Ironwood Pharmaceuticals, Inc. (IRWD)
NASDAQ: IRWD · Real-Time Price · USD
4.420
+0.190 (4.49%)
At close: Aug 3, 2026, 4:00 PM EDT
4.370
-0.050 (-1.13%)
After-hours: Aug 3, 2026, 4:10 PM EDT
Ironwood Pharmaceuticals Employees
Ironwood Pharmaceuticals had 100 employees as of December 31, 2025. The number of employees decreased by 153 or -60.47% compared to the previous year.
Employees
100
Change (1Y)
-153
Growth (1Y)
-60.47%
Revenue / Employee
$3,615,140
Profits / Employee
$1,021,760
Market Cap
727.59M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 100 | -153 | -60.47% |
| Dec 31, 2024 | 253 | -14 | -5.24% |
| Dec 31, 2023 | 267 | 48 | 21.92% |
| Dec 31, 2022 | 219 | 0 | - |
| Dec 31, 2021 | 219 | -13 | -5.60% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Evotec SE | 4,526 |
| Tilray Brands | 2,842 |
| Amphastar Pharmaceuticals | 1,976 |
| Canopy Growth | 1,128 |
| Pacira BioSciences | 829 |
| Cronos Group | 610 |
| Kamada | 462 |
| Glass House Brands | 426 |
IRWD News
- 4 days ago - Ironwood Pharmaceuticals to Host Second Quarter 2026 Investor Update Call - Business Wire
- 20 days ago - Ironwood CMO Michael Shetzline to retire, Jeffrey Silber to succeed - TheFly
- 20 days ago - Ironwood Appoints Dr. Jeffrey Silber Chief Medical Officer and Head of Research and Drug Development; STARS-2 Trial Initiated in June and Is Now Actively Recruiting Patients - Business Wire
- 2 months ago - Ironwood Pharmaceuticals Transcript: Jefferies Global Healthcare Conference 2026 - Transcripts
- 2 months ago - Ironwood Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference - Business Wire
- 2 months ago - Ironwood says FDA approves use of Linzess in pediatric patients two and older - TheFly
- 2 months ago - FDA Approves Use of LINZESS® (linaclotide) in Pediatric Patients Two Years of Age and Older with Functional Constipation (FC) - Business Wire
- 3 months ago - Ironwood Pharmaceuticals Earnings Call Transcript: Q1 2026 - Transcripts